ABT Abbott Laboratories Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: 48
Relative Profitability: Rel. Profitability: 64

EPS in 2026 (TTM): $3.59

Last Report Period Date: Mar 31, 2026

As of June this year, based on Abbott Laboratories's most recent financial report, the company's trailing twelve months EPS is $3.59. Abbott Laboratories's earnings per share in 2025 was reported at $3.73, marking a decline from $7.67 in 2024. Abbott Laboratories's EPS for the quarterly period ending on Mar 31, 2026 came in at $0.62.

ABT earnings history

Historical annual and quarterly earnings per share (EPS) data for Abbott Laboratories
EPS (TTM)
$3.59
EPS Growth YoY (Quarterly)
-18.4%
EPS (Quarterly)
$0.62
EPS Growth (Quarterly)
-38.6%

The yearly earnings per share during 2025 was $3.73, a decline of 51.4% compared to $7.67 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was $0.62, showing a 18.4% decline compared to the same quarter last year. The trailing twelve months EPS for ABT is $3.59 as of March 2026. Abbott Laboratories's full-year EPS for 2024 was $7.67, a 133.8% rise compared to the previous year.

ABT earnings chart

ABT EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-18.4%
EPS growth YoY
-51.4%
EPS growth 3Y avg
-1.8%
EPS growth 5Y avg
8.2%

In the past 12 months, Abbott Laboratories has recorded an earnings per share growth rate of -18.4% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of -1.8% per year. In the last five years, the company had an average annual EPS growth of 8.2%. When assessed over a ten-year period, ABT's average EPS annual growth was 2.4%.

ABT Earnings Waterfall

Breakdown of revenue, profit and net income for Abbott Laboratories

ABT Earnings vs Peers

What are the earnings of ABT compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 15.52 178.7% 5.3% N/A
BSX Boston Scientific Corp 18.72 55.6% 63.3% N/A
PFE Pfizer Inc 18.97 -3.5% -37.4% -3.7%
MDT Medtronic plc 21.39 3.3% 9.8% 6.9%
NVS Novartis AG 21.74 21.8% 31.2% 15.2%
ABT Abbott Laboratories 25.18 -51.4% -1.8% 8.2%
TMO Thermo Fisher Scientific Inc 25.49 7.2% 0% 2%
AZN Astrazeneca plc 26.8 45.4% 46% 22%
JNJ Johnson & Johnson 27.02 90.6% 17.7% 14.8%

All data is based on quarterly TTM periods, unless otherwise specified.